Investment Banking Services

on a Global Basis

Triad Healthcare Partners

Triad Healthcare Partners, a division of Triad Securities Corp., provides investment banking services to pharmaceutical and medical device companies on a global basis. The team has a particular focus in the specialty pharmaceutical sector.

Andrew Hirschberg and Mark Palmer work with specialty pharmaceutical clients to provide strategic advisory services related to all aspects of mergers, acquisitions and licensing activities on a global basis.

Andrew Hirschberg has been advising specialty pharmaceutical clients for 30 years and has completed over 100 transactions in multiple specialties (dermatology, gastroenterology, pediatrics, nephrology, etc.) with an aggregate value exceeding $5 billion.

Mark Palmer led business development for two specialty pharmaceutical companies (Braintree Laboratories, Inc. and Medicis Pharmaceutical Corp.) for the ten years prior to joining Triad Healthcare Partners. During that time, Mark led and completed transactions with an aggregate value of well over $1 billion. These transactions were primarily in dermatology, gastroenterology, orphan drugs and pediatrics.

Prior to forming Triad Healthcare Partners, Andrew and Mark worked together as investment bankers at another broker-dealer, where they advised clients on strategic transactions and completed multiple M&A and licensing deals.

Andrew and Mark work with companies throughout the development and commercialization timeline and assist with in/out-licensing and mergers and acquisitions to maximize value for the shareholders of client companies. They have vast experience in sourcing deals and representing clients in all aspects of deal making and negotiation in the global specialty pharmaceutical marketplace.

Mergers and Acquisitions

Andrew Hirschberg
Head of Investment Banking
Triad Healthcare Partners

(203) 258-7008

Mergers and Acquisitions

Mark Palmer
Managing Director
Triad Healthcare Partners

(602) 621-1429

Representative Transactions

Client Transaction Counterparty Deal Valuation
Medicis Sale of Company Valeant $2.6 B
MerzPharma Company Acquisition Ulthera Up to $600M
Revision Skincare/Goodier Cosmetics Majority Stake Sold RoundTable Healthcare Undisclosed
Novan, Inc. Out-license of SB204 (Phase 3, acne) for Japan Sato Pharmaceutical Co. Up $42.4M + Royalties
Merz Pharma Sale of Dermatology Assets Sebela Pharmaceuticals Undisclosed
Neocutis SA Sale of Company Merz Pharma Undisclosed
Brickell Biotech Out-license of hyperhidrosis asset (Phase 2) for Japan/other Asian countries Kaken Pharmaceutical Undisclosed
Medicis Acquisition of Company's Assets Graceway Pharmaceuticals $455 M
Precision Dermatology Acquisition of Clindagel Assets Galderma Laboratories Undisclosed
Braintree Laboratories Sale of PhosLo Product Line Nabi Biopharmaceuticals $120 M
Ivax Acquisition of Nasarel and Nasalide Prod. Lines Elan Corporation $140 M
Hill Dermaceuticals Sale of Triluma Product Line Galderma Laboratories $100 M+
R&D Laboratories Sale of Company Watson Pharmaceuticals $185 M
Braintree Laboratories Out-license of SuPrep For 50-countries (Ex-North America) Ipsen Group Undisclosed
Medicis Sale of Ascent Pediatrics BioMarin Pharmaceutical $190 M
Ferndale Laboratories Sale of Locoid Product Line Triax Pharmaceuticals $120 M
Daniels Pharmaceuticals Sale of Company Jones Medical Industries $130 M
Braintree Labratories Sale of MiraLax OTC Rights Schering-Plough Undisclosed